27,347 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 27,347 shares of the biotechnology company’s stock, valued at approximately $1,816,000.

A number of other institutional investors have also made changes to their positions in ARWR. Royal Bank of Canada increased its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 10,496 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth approximately $514,000. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after acquiring an additional 447,456 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 979 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% during the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 15,123 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ARWR shares. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Chardan Capital boosted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. B. Riley Financial boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $84.20.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $74.81 on Monday. The business has a fifty day simple moving average of $63.47 and a 200 day simple moving average of $59.52. The company has a market capitalization of $10.48 billion, a PE ratio of 48.90 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $12.44 and a 1 year high of $76.76. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.39) earnings per share. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer directly owned 162,905 shares in the company, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider owned 226,958 shares of the company’s stock, valued at approximately $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 33,095 shares of company stock valued at $2,326,228 over the last 90 days. 3.60% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.